Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context

Badrinath R. Konety, Vikram M. Narayan, Colin P.N. Dinney

Research output: Contribution to journalReview article

Abstract

High-risk non–muscle invasive bladder cancer is marked by frequent disease recurrences and risk of stage progression, contributing to high surveillance, treatment-related costs, and patient anxiety. Although the mainstay of high-risk non–muscle invasive bladder cancer clinical management remains transurethral resection followed by intravesical bacillus Calmette-Guérin (BCG), patients who develop BCG-unresponsive disease have few salvage options outside of a radical cystectomy with pelvic lymphadenectomy. This article provides a historical context relevant to the development of the BCG-unresponsive definition, an overview of current clinical trial expectations, and an introduction to this issue of Urologic Clinics.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalUrologic Clinics of North America
Volume47
Issue number1
DOIs
StatePublished - Feb 2020

Fingerprint

Salvage Therapy
Bacillus
Urinary Bladder Neoplasms
Cystectomy
Lymph Node Excision
Health Care Costs
Meta-Analysis
Anxiety
Recurrence

Keywords

  • BCG failure
  • BCG-unresponsive disease
  • Definitions of BCG-unresponsive
  • High-risk non–muscle invasive bladder cancer
  • Salvage intravesical therapy
  • Society of Urologic Oncology Clinical Trials Consortium

ASJC Scopus subject areas

  • Urology

Cite this

Bacillus Calmette-Guérin Salvage Therapy : Definitions and Context. / Konety, Badrinath R.; Narayan, Vikram M.; Dinney, Colin P.N.

In: Urologic Clinics of North America, Vol. 47, No. 1, 02.2020, p. 1-4.

Research output: Contribution to journalReview article

Konety, Badrinath R. ; Narayan, Vikram M. ; Dinney, Colin P.N. / Bacillus Calmette-Guérin Salvage Therapy : Definitions and Context. In: Urologic Clinics of North America. 2020 ; Vol. 47, No. 1. pp. 1-4.
@article{a9d3d795bbc145aeb063c898517129e5,
title = "Bacillus Calmette-Gu{\'e}rin Salvage Therapy: Definitions and Context",
abstract = "High-risk non–muscle invasive bladder cancer is marked by frequent disease recurrences and risk of stage progression, contributing to high surveillance, treatment-related costs, and patient anxiety. Although the mainstay of high-risk non–muscle invasive bladder cancer clinical management remains transurethral resection followed by intravesical bacillus Calmette-Gu{\'e}rin (BCG), patients who develop BCG-unresponsive disease have few salvage options outside of a radical cystectomy with pelvic lymphadenectomy. This article provides a historical context relevant to the development of the BCG-unresponsive definition, an overview of current clinical trial expectations, and an introduction to this issue of Urologic Clinics.",
keywords = "BCG failure, BCG-unresponsive disease, Definitions of BCG-unresponsive, High-risk non–muscle invasive bladder cancer, Salvage intravesical therapy, Society of Urologic Oncology Clinical Trials Consortium",
author = "Konety, {Badrinath R.} and Narayan, {Vikram M.} and Dinney, {Colin P.N.}",
year = "2020",
month = "2",
doi = "10.1016/j.ucl.2019.09.002",
language = "English (US)",
volume = "47",
pages = "1--4",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Bacillus Calmette-Guérin Salvage Therapy

T2 - Definitions and Context

AU - Konety, Badrinath R.

AU - Narayan, Vikram M.

AU - Dinney, Colin P.N.

PY - 2020/2

Y1 - 2020/2

N2 - High-risk non–muscle invasive bladder cancer is marked by frequent disease recurrences and risk of stage progression, contributing to high surveillance, treatment-related costs, and patient anxiety. Although the mainstay of high-risk non–muscle invasive bladder cancer clinical management remains transurethral resection followed by intravesical bacillus Calmette-Guérin (BCG), patients who develop BCG-unresponsive disease have few salvage options outside of a radical cystectomy with pelvic lymphadenectomy. This article provides a historical context relevant to the development of the BCG-unresponsive definition, an overview of current clinical trial expectations, and an introduction to this issue of Urologic Clinics.

AB - High-risk non–muscle invasive bladder cancer is marked by frequent disease recurrences and risk of stage progression, contributing to high surveillance, treatment-related costs, and patient anxiety. Although the mainstay of high-risk non–muscle invasive bladder cancer clinical management remains transurethral resection followed by intravesical bacillus Calmette-Guérin (BCG), patients who develop BCG-unresponsive disease have few salvage options outside of a radical cystectomy with pelvic lymphadenectomy. This article provides a historical context relevant to the development of the BCG-unresponsive definition, an overview of current clinical trial expectations, and an introduction to this issue of Urologic Clinics.

KW - BCG failure

KW - BCG-unresponsive disease

KW - Definitions of BCG-unresponsive

KW - High-risk non–muscle invasive bladder cancer

KW - Salvage intravesical therapy

KW - Society of Urologic Oncology Clinical Trials Consortium

UR - http://www.scopus.com/inward/record.url?scp=85075151777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075151777&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2019.09.002

DO - 10.1016/j.ucl.2019.09.002

M3 - Review article

C2 - 31757292

AN - SCOPUS:85075151777

VL - 47

SP - 1

EP - 4

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 1

ER -